Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Published:2013-09-26 Issue:13 Volume:122 Page:2286-2288
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Santini Valeria¹,Schemenau Jennifer²,Levis Alessandro³,Balleari Enrico⁴,Sapena Rosa⁵,Adès Lionel⁶,Guerci Agnès⁷,Beyne-Rauzy Odile⁸,Gourin Marie-Pierre⁹,Cheze Stephane¹⁰,Stamatoullas Aspasia¹¹,Sanna Alessandro¹,Gioia Daniela¹²,Cametti Gianni¹³,Ferrero Dario¹⁴,Raffoux Emmanuel¹⁵,Rose Christian¹⁶,Poloni Antonella¹⁷,Prebet Thomas¹⁸,Legros Laurence¹⁹,Natarajan-Amé Shanti²⁰,Fenaux Pierre²¹,Germing Ulrich²,Dreyfus François²²,Park Sophie²³

Affiliation:

1. Fundazion Italiana delle sindromi mielodisplastiche, Florence, Italy

2. Heinrich-Heine University, Düsseldorf, Germany

3. ASO Santi Antonio e Biagio, Düsseldorf, Germany

4. University of Genoa, Genoa, Italy

5. Groupe Francophone des Myélodysplasies, Paris, France

6. Hopital Avicenne, Paris, France

7. Centre Hospitalo Universitaire, Nancy, France

8. Centre Hospitalo Universitaire, Toulouse Purpan, Toulouse, France

9. Groupe Francophone des Myélodysplasies, Limoges, France

10. Groupe Francophone des Myélodysplasies, Caen, France

11. Groupe Francophone des Myélodysplasies, Rouen, France

12. Fundazion Italiana delle sindromi mielodisplastiche, Alessandria, Italy

13. Fundazion Italiana delle sindromi mielodisplastiche, Chieri, Italy

14. Fundazion Italiana delle sindromi mielodisplastiche, Torino, Italy

15. Hospital Saint Louis, Paris, France

16. Hopital Saint Vincent de Paul, Université Catholique de Lille, Lille, France

17. Universita Politecnica delle Marche, Ancona, Italy

18. Groupe Francophone des Myélodysplasies, Marseille, France

19. Groupe Francophone des Myélodysplasies, Nice, France

20. Hopital Civil, Centre Hospitalo Universitaire, Strasbourg, France

21. Hopital Avicenne, Paris 13 University, Paris, France

22. Hopital Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France

23. Centre Hospitalo Universitaire, Grenoble, France

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/13/2286/1368236/2286.pdf

Reference5 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes.;Greenberg;Blood,1997

2. Revised international prognostic scoring system for myelodysplastic syndromes.;Greenberg;Blood,2012

3. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.;Schanz;J Clin Oncol,2012

4. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.;Hellström-Lindberg;Br J Haematol,2003

5. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.;Kelaidi;Leukemia,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial;Leukemia;2024-01-31

2. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet;2024-01

3. Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes;Therapeutic Advances in Hematology;2024-01

4. Traitement des syndromes myélodysplasiques de bas risque;Bulletin du Cancer;2023-11

5. Raising the bar for lower-risk myelodysplastic syndromes;Leukemia & Lymphoma;2023-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3